دورية أكاديمية
Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study.
| العنوان: | Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study. |
|---|---|
| المؤلفون: | Gao R; Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Li C; Department of Breast Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhang S; Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Liao N; Department of Breast Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. syliaoning@scut.edu.cn., Guan H; Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. guanhaixia@gdph.org.cn. |
| المصدر: | Endocrine [Endocrine] 2024 Sep; Vol. 85 (3), pp. 1446-1455. Date of Electronic Publication: 2024 Jun 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Humana Press Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Feb. 1996- : Totowa, NJ : Humana Press Original Publication: Houndsmills, Basingstoke, Hants, UK : Macmillan Press, c1994- |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy , Immune Checkpoint Inhibitors*/adverse effects , Endocrine System Diseases*/chemically induced , Endocrine System Diseases*/epidemiology, Humans ; Female ; Middle Aged ; Adult ; Aged ; Retrospective Studies ; Incidence |
| مستخلص: | Purpose: This study aims to systematically evaluate the incidence of immune checkpoint inhibitors (ICIs)-related endocrinopathies and their onset time in patients with breast cancer (BC) in a real-world setting. Methods: An analysis was conducted on the medical records of 122 BC patients who underwent ICIs therapy at the Department of Breast Surgery, Guangdong Provincial People's Hospital, from April 2019 to September 2021. Follow-up data continued until October 2022. Results: The research indicated that 60.66% of BC patients experienced ICI-related endocrinopathies. The endocrinopathies included pituitary injury (7.38%), primary thyroid dysfunction (34.43%), supranormal fasting blood glucose or glycohemoglobin levels (16.39%), and adrenal injury (2.46%). Subgroup analyses were further performed based on clinical characteristics, demonstrated variability in the incidence of ICI-related endocrinopathies. Notably, subpopulations harboring genetic mutations exhibited a markedly higher prevalence of hypophysitis, as evidenced by a statistically significant association (P = 0.022). Similarly, individuals with HER2 positivity were found to have a significantly increased incidence of pancreatic islet injury (P = 0.023). Moreover, the study documented that the median onset times of ICIs-related endocrinopathies in pituitary, thyroid, pancreatic, and adrenal damage were 264, 184, 99 and 141 days, respectively, which were substantially longer compared to previous reports involving other tumors. Remarkably, even after 500 days of initiating ICI therapy, new cases of ICI-related endocrine disorders continue to emerge, suggesting a situation of delayed onset of ICI-related endocrinopathies in BC patients. Conclusion: The retrospective analysis confirmed a higher incidence and longer median onset time of ICI-related endocrinopathies in BC patients compared to other cancers. These outcomes underscore the critical need for regular and extended monitoring of endocrine functions in BC patients receiving ICI therapy, advocating for personalized monitoring approaches based on individual clinical profiles. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | S. Zhao, X.Y. Liu, X. Jin, D. Ma, Y. Xiao, Z.M. Shao, Y.Z. Jiang, Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. Theranostics 9(17), 4935–4945 (2019). (PMID: 10.7150/thno.35730314101926691389) P. Schmid, J. Cortes, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9), 810–821 (2020). (PMID: 10.1056/NEJMoa191054932101663) J. Cortes, D.W. Cescon, H.S. Rugo, Z. Nowecki, S.A. Im, M.M. Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, E. Holgado et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265), 1817–1828 (2020). (PMID: 10.1016/S0140-6736(20)32531-933278935) J. Cortes, H.S. Rugo, D.W. Cescon, S.A. Im, M.M. Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, J. Perez-Garcia, H. Iwata et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387(3), 217–226 (2022). (PMID: 10.1056/NEJMoa220280935857659) P. Schmid, S. Adams, H.S. Rugo, A. Schneeweiss, C.H. Barrios, H. Iwata, V. Diéras, R. Hegg, S.A. Im, G. Shaw Wright et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379(22), 2108–2121 (2018). (PMID: 10.1056/NEJMoa180961530345906) P. Schmid, H.S. Rugo, S. Adams, A. Schneeweiss, C.H. Barrios, H. Iwata, V. Diéras, V. Henschel, L. Molinero, S.Y. Chui et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1), 44–59 (2020). (PMID: 10.1016/S1470-2045(19)30689-831786121) C.F. Friedman, T.A. Proverbs-Singh, M.A. Postow, Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2(10), 1346–1353 (2016). (PMID: 10.1001/jamaoncol.2016.105127367787) M.A. Postow, R. Sidlow, M.D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378(2), 158–168 (2018). (PMID: 10.1056/NEJMra170348129320654) L.S. Chang, R. Barroso-Sousa, S.M. Tolaney, F.S. Hodi, U.B. Kaiser, L. Min, Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 40(1), 17–65 (2019). (PMID: 10.1210/er.2018-0000630184160) F. Albarel, F. Castinetti, T. Brue, MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181(3), R107-r118 (2019). J.S. Weber, K.C. Kähler, A. Hauschild, Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21), 2691–2697 (2012). (PMID: 10.1200/JCO.2012.41.675022614989) J.D. Yager, N.E. Davidson, Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3), 270–282 (2006). (PMID: 10.1056/NEJMra05077616421368) B. Trabert, M.E. Sherman, N. Kannan, F.Z. Stanczyk, Progesterone and Breast Cancer. Endocr Rev 41(2), 320–344 (2020). (PMID: 10.1210/endrev/bnz00131512725) S. Loibl, P. Poortmans, M. Morrow, C. Denkert, G. Curigliano, Breast cancer. Lancet 397(10286), 1750–1769 (2021). (PMID: 10.1016/S0140-6736(20)32381-333812473) C.N. Owen, X. Bai, T. Quah, S.N. Lo, C. Allayous, S. Callaghan, C. Martínez-Vila, R. Wallace, P. Bhave, I.L.M. Reijers et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32(7), 917–925 (2021). (PMID: 10.1016/j.annonc.2021.03.20433798657) M.A. Couey, R.B. Bell, A.A. Patel, M.C. Romba, M.R. Crittenden, B.D. Curti, W.J. Urba, R.S. Leidner, Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1), 165 (2019). (PMID: 10.1186/s40425-019-0645-6312699836609357) O. Nigro, G. Pinotti, F. De Galitiis, F.R. Di Pietro, R. Giusti, M. Filetti, M. Bersanelli, A. Lazzarin, P. Bordi, A. Catino et al. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. Eur J Cancer 134, 19–28 (2020). (PMID: 10.1016/j.ejca.2020.04.02532454395) J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau, M.S. Ernstoff, J.M. Gardner, P. Ginex et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17), 1714–1768 (2018). (PMID: 10.1200/JCO.2017.77.638529442540) J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7), 389–399 (2021). (PMID: 10.1038/s41574-021-00484-3338758578769055) M.H. Tan, R. Iyengar, K. Mizokami-Stout, S. Yentz, M.P. MacEachern, L.Y. Shen, B. Redman, R. Gianchandani, Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol 5, 1 (2019). (PMID: 10.1186/s40842-018-0073-4306930996343255) J.H.L. Chieng, Z.W. Htet, J. J. Zhao, E.S. Tai, S. H. Tay, Y. Huang, A. Wong, S.P. Yang, Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers (Basel) 14(11), 2687 (2022). R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop, S.M. Tolaney, Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 4(2), 173–182 (2018). (PMID: 10.1001/jamaoncol.2017.306428973656) B. Shankar, J. Zhang, A.R. Naqash, P.M. Forde, J.L. Feliciano, K.A. Marrone, D.S. Ettinger, C.L. Hann, J.R. Brahmer, B. Ricciuti et al. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol 6(12), 1952–1956 (2020). (PMID: 10.1001/jamaoncol.2020.501233119034) A. D’Aiello, J. Lin, R. Gucalp, V. Tabatabaie, H. Cheng, N.A. Bloomgarden, Y. Tomer, B. Halmos, Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers (Basel), 13(6), 1464 (2021). S. Bacanovic, I.A. Burger, P. Stolzmann, J. Hafner, M.W. Huellner, Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT. Clin Nucl Med 40(11), e518–e519 (2015). (PMID: 10.1097/RLU.000000000000088726164177) J. de Filette, C.E. Andreescu, F. Cools, B. Bravenboer, B. Velkeniers, A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 51(3), 145–156 (2019). (PMID: 10.1055/a-0843-336630861560) A.M. Grimaldi, F.M. Marincola, P.A. Ascierto, Single versus combination immunotherapy drug treatment in melanoma. Expert Opin Biol Ther 16(4), 433–441 (2016). (PMID: 10.1517/14712598.2016.112889126642234) J. Haanen, F. Carbonnel, C. Robert, K.M. Kerr, S. Peters, J. Larkin, K. Jordan,Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4), iv264–iv266 (2018). (PMID: 10.1093/annonc/mdy16229917046) P. Iglesias, Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. Eur J Intern Med 47, 6–13 (2018). (PMID: 10.1016/j.ejim.2017.08.01928826822) L. Min, N. Ibrahim, Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 1(3), e15 (2013). (PMID: 10.1016/S2213-8587(13)70031-7246223754106239) S. Osanto, T. van der Hulle, Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol 10(3), 109–123 (2018). (PMID: 10.1177/1756287217748867296625415896860) S.A. Weiss, J.D. Wolchok, M. Sznol, Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res 25(17), 5191–5201 (2019). (PMID: 10.1158/1078-0432.CCR-18-1550309230366726509) I.F. Muhammad, Y. Borné, X. Bao, O. Melander, M. Orho-Melander, P.M. Nilsson, J. Nilsson, G. Engström, Circulating HER2/ErbB2 Levels Are Associated With Increased Incidence of Diabetes: A Population-Based Cohort Study. Diabetes Care 42(8), 1582–1588 (2019). (PMID: 10.2337/dc18-255631201260) L. Juanjuan, W. Wen, L. Zhongfen, C. Chuang, C. Jing, G. Yiping, W. Changhua, Y. Dehua, S. Shengrong, Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study. Tumour Biol 36(9), 6939–6947 (2015). (PMID: 10.1007/s13277-015-3380-825854171) |
| معلومات مُعتمدة: | 32300640 National Natural Science Foundation of China; 82170803 National Natural Science Foundation of China; KJ012020629 GDPH Supporting Fund for Talent Program |
| فهرسة مساهمة: | Keywords: Breast cancer; Endocrinopathies; Hormone receptor.; Immune checkpoint inhibitors; Thyroid dysfunction |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240701 Date Completed: 20240810 Latest Revision: 20240810 |
| رمز التحديث: | 20240812 |
| DOI: | 10.1007/s12020-024-03859-4 |
| PMID: | 38951449 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1559-0100 |
|---|---|
| DOI: | 10.1007/s12020-024-03859-4 |